DMS • 1 Rope Ferry Road • Hanover, NH 03755-1404 • Voice 603 650-1200 • Fax 603 650-1202 • Toll Free 1 877 DMS 1797

| | |

William F.C. Rigby, M.D.

Title(s):
Professor of Medicine, and of Microbiology and Immunology

Department(s):
Medicine
Microbiology and Immunology

Education:
Harvard Medical School, MD 1979
Columbia University, BA 1974


After postdoctoral work in Dr. Michael Fanger's laboratory in the Department of Microbiology at Dartmouth Medical School, Dr. Rigby completed subspecialty training in rheumatology and joined the faculty at Dartmouth Medical School in 1987.

Programs:
Immunology Program
Neuroscience Center at Dartmouth
Program in Experimental and Molecular Medicine

NIH Biosketch:
Rigby_W_BIO_2009-01-30.pdf

Websites:
http://dms.dartmouth.edu/microbio/
http://dms.dartmouth.edu/immuno/
http://dms.dartmouth.edu/COBRE/

Contact Information:

Dartmouth Hitchcock Medical Center
Borwell Research Bldg. - HB 7510
1 Medical Center Drive
Lebanon NH 03756
Phone: 603-650-7700
Fax: 603-650-6223
Email: William.Rigby@Dartmouth.EDU

Assistant: Linda Jarvis
Asst. Phone: 603-650-7700
Asst. Email: Linda.L.Jarvis@Hitchcock.ORG


Selected Publications:

 

Antiochos BB, Brown LA, Li Z, Tosteson TD, Wortmann RL, Rigby WF
Malignancy Is Associated with Dermatomyositis But Not Polymyositis in Northern New England, USA.
J Rheumatol 2009 Nov 16; ():
PMID: 19918034 [PubMed - as supplied by publisher]

Hamilton BJ, Wang XW, Collins J, Bloch D, Bergeron A, Henry B, Terry BM, Zan M, Mouland AJ, Rigby WF
Separate cis-trans pathways post-transcriptionally regulate murine CD154 (CD40 ligand) expression: a novel function for CA repeats in the 3'-untranslated region.
J Biol Chem 2008 Sep 12; 283(37):25606-16
PMID: 18640985 [PubMed - indexed for MEDLINE]

Huarte E, Cubillos-Ruiz JR, Nesbeth YC, Scarlett UK, Martinez DG, Engle XA, Rigby WF, Pioli PA, Guyre PM, Conejo-Garcia JR
PILAR is a novel modulator of human T-cell expansion.
Blood 2008 Aug 15; 112(4):1259-68
PMID: 18550855 [PubMed - indexed for MEDLINE]

Rigby WF
Drug insight: different mechanisms of action of tumor necrosis factor antagonists-passive-aggressive behavior?
Nat Clin Pract Rheumatol 2007 Apr; 3(4):227-33
PMID: 17396108 [PubMed - indexed for MEDLINE]

Rigby WF, Roy K, Collins J, Rigby S, Connolly JE, Bloch DB, Brooks SA
Structure/function analysis of tristetraprolin (TTP): p38 stress-activated protein kinase and lipopolysaccharide stimulation do not alter TTP function.
J Immunol 2005 Jun 15; 174(12):7883-93
PMID: 15944294 [PubMed - indexed for MEDLINE]

Rigby WF
Distinct mechanisms of action of tumor necrosis factor antagonists: what are the clinical implications?
Semin Arthritis Rheum 2005 Apr; 34(5 Suppl1):1-2
PMID: 15852246 [PubMed - indexed for MEDLINE]

Brooks SA, Connolly JE, Rigby WF
The role of mRNA turnover in the regulation of tristetraprolin expression: evidence for an extracellular signal-regulated kinase-specific, AU-rich element-dependent, autoregulatory pathway.
J Immunol 2004 Jun 15; 172(12):7263-71
PMID: 15187101 [PubMed - indexed for MEDLINE]

Hamilton BJ, Genin A, Cron RQ, Rigby WF
Delineation of a novel pathway that regulates CD154 (CD40 ligand) expression.
Mol Cell Biol 2003 Jan; 23(2):510-25
PMID: 12509450 [PubMed - indexed for MEDLINE]

Brooks SA, Connolly JE, Diegel RJ, Fava RA, Rigby WF
Analysis of the function, expression, and subcellular distribution of human tristetraprolin.
Arthritis Rheum 2002 May; 46(5):1362-70
PMID: 12115244 [PubMed - indexed for MEDLINE]

Pioli PA, Hamilton BJ, Connolly JE, Brewer G, Rigby WF
Lactate dehydrogenase is an AU-rich element-binding protein that directly interacts with AUF1.
J Biol Chem 2002 Sep 20; 277(38):35738-45
PMID: 12107167 [PubMed - indexed for MEDLINE]


Professional Interests:

Dr. Rigby's laboratory integrates his basic scientific and clinical interests. On a translational level, Dr. Rigby is examining the changes that accompany clinical responses in patients with rheumatoid arthritis treated with biologics. His basic scientific efforts examine the mechanism by which CD40 ligand (CD154) and cytokine expression are regulated at post-transcriptional levels. Many cytokines are encoded by mRNA that contain reiterated AUUUA sequences in their 3' UTR. These AU-rich sequences (AURE) have been shown to modulate the translation as well as rapid degradation of these mRNA. His laboratory has been active in identifying proteins that bind to AURE and regulate these events. Of late, he has studied the regulation of CD154 (CD40 ligand), a member of the TNF gene family that plays a critical role in the immune response. In contrast to cytokine genes, CD154 is regulated by its rate of cytoplasmic mRNA turnover and translation. The CD154 3'UTR mRNA contains two separate cis-acting elements, the cytidine-uridine (CU)- and cytidine-adenine (CA)-rich elements that respectively regulate these two activities. Interestingly the CA rich element is polymorphic in the human; certain polymorphisms have been associated with the development of rheumatoid arthritis and systemic lupus erythematosus.

These findings have prompted Dr. Rigby to begin translational studies of patients with rheumatologic disease to determine if: a) CD154 dysregulation is present; b) Is this dysregulation influenced by disease activity; c) Does this dysregulation correlate with CA-repeat polymorphisms? In this manner, Dr. Rigby will begin to address epigenetic and genetic factors that regulate the expression of this critical immunoregulatory molecule.

Copyright © 2009 Trustees of Dartmouth College

Feedback